Full-Time

Area Business Manager

Blueprint Medicines

Blueprint Medicines

501-1,000 employees

Biopharma developing kinase inhibitors for cancer

Compensation Overview

$190k - $230k/yr

+ Incentive Compensation

Madison, WI, USA + 1 more

More locations: Milwaukee, WI, USA

In Person

Resides within the territory.

Category
Sales & Account Management (1)
Requirements
  • BA/BS degree required or bachelor’s degree
  • 5+ years’ experience in biotech/pharma sales calling on relevant specialists
  • 5+ years experience experience in Allergy/Immunology, Hematology, and/or Rare Disease
  • Resides within the territory
Responsibilities
  • Apply strong clinical acumen to effectively educate on relevant products and disease states to target healthcare professionals; oncologists, hematologists, allergists, immunologists, as well as the broader care team in academic and community practice settings
  • Apply strong business acumen to effectively build relationships and manage accounts by engaging a variety of healthcare stakeholders including account leadership, mid-level providers, nursing, pharmacy, and patient access support functions
  • Engage accounts on patient pull-though strategies including dispensing support, patient access engagement, and patient management strategies to ensure appropriate utilization
  • Exhibit a patient focused mindset while delivering educational resources and programs to assist with effective patient care
  • Build and maintain relationships with key accounts and customers, involving cross-functional stakeholders as needed to manage key relationships of national and/or regional relevance
  • Builds collaborative partnerships and operates effectively in a matrix environment; expert collaboration with cross-functional partners, including marketing, training, operations, advocacy, medical, etc.
  • Builds relationships and maintains effective communication with internal stakeholders
  • Develop effective business plans aimed at achieving set objectives
  • Proactively identify new opportunities and apply customer insights to develop, execute and refine approaches
  • Leverage analytical tools to understand business trends and meet or exceed target KPIs
  • Represent Blueprint Medicines at congresses and local / regional medical meetings
  • Ability to travel within the US on a regular basis, which may include overnight and weekend travel
  • Comply with regulatory guidelines, public policies/guidelines, and corporate policies and procedures
  • Perform other responsibilities as assigned.
Desired Qualifications
  • Degree preferably in Health Sciences, Business, Marketing, Accounting, or related field
  • Allergy/Immunology preferred
  • Consistent success in driving above-plan sales results within a specific region/territory
  • Strong clinical background in applicable specialties is required; oncology, hematology, allergy/immunology. Rare disease experience is preferred.
  • Product launch experience, preferably at small to mid-size companies is preferred
  • Understanding of disease modifying therapies with a requisite diagnostic component and ability to navigate patient pull through in complex market access environments
  • Proficiency in working with specialty drugs via a HUB distribution model is preferred
  • Proven ability to develop and expand new markets.
  • Adept at utilizing educational resources, data, and programs to ensure a positive patient and provider experience
  • Exceptional interpersonal and communication skills to form strong, trusting partnerships to drive performance
  • Robust analytical and problem-solving skills, ability to identify and action on creative solutions
  • Ability to establish credibility, connect the dots and align multiple stakeholders to pioneer the adoption of new products, methods and technologies
  • A team player able to collaborate effectively with a broad range of stakeholders, gain consensus and act independently in a fast-paced, entrepreneurial environment
  • Flexibility and the ability to plan and nimbly adapt to changing market conditions
  • Motivated by patient focus, urgency and personal commitment to high performance, results and compliance
  • Possesses high integrity and exceptional work ethic
  • Commitment to our Core Values: Patients First, Thoughtfulness, Urgency, Trust, Optimism

Blueprint Medicines develops and commercializes kinase inhibitors for cancer and other diseases. Its lead product, Ayvakit (avapritinib), blocks enzymes that drive tumor growth in gastrointestinal stromal tumors with PDGFRA exon 18 mutations. The company also has a pipeline of other kinase inhibitors in clinical development for lung, breast, and blood cancers, plus preclinical programs in immunology and rare diseases. By performing discovery, development, and commercialization in-house, it aims to bring targeted therapies to patients with unmet medical needs and expand its global oncology portfolio.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2011

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi $9.1B acquisition on June 2, 2025, boosts immunology portfolio and resources.
  • AI and machine learning enhance drug discovery productivity since recent integration.
  • Targeted protein degradation expansion via 2022 VantAI collaboration diversifies pipeline.

What critics are saying

  • Sanofi integration disrupts sales force, eroding Ayvakit market share in 12-18 months.
  • FDA black box warnings for Ayvakit hemorrhage drop prescriptions 20-30% in 6-12 months.
  • Generic avapritinib from Dr. Reddy's captures 40% GIST market by 2028.

What makes Blueprint Medicines unique

  • Ayvakit is the only FDA-approved treatment targeting PDGFRA D842V mutations in GIST.
  • PIONEER four-year data confirm AYVAKIT's sustained efficacy in indolent systemic mastocytosis.
  • BLU-808 shows wide therapeutic window as first-in-class oral wild-type KIT inhibitor.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Blueprint Medicines who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Commuter Benefits

Mental Health Support

Employee Stock Purchase Plan

Parental Leave

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

5%

2 year growth

3%
Fusacq
Jun 2nd, 2025
Sanofi Acquires Blueprint Medicines Biotech

Sanofi has acquired the American biotech company Blueprint Medicines, which specializes in systemic mastocytosis, a rare disease characterized by abnormal activation or proliferation of mast cells in tissues, most commonly the skin and bone marrow.

Google
Jun 2nd, 2025
Sanofi Acquires Blueprint for $9.1B

Sanofi is set to acquire Blueprint Medicines for an equity value of $9.1 billion, according to Bloomberg.

Investors Hangout
Jun 2nd, 2025
Sanofi Acquires Blueprint for $9.1B

Sanofi is acquiring Blueprint Medicines for approximately $9.1 billion, enhancing its immunology portfolio. This acquisition includes Ayvakit, the only FDA-approved treatment for systemic mastocytosis, and promising therapies like elenestinib and BLU-808. Sanofi will finance the deal with cash and new debt, expecting it to boost gross margin and operating income post-2026. The merger aligns with Sanofi's strategy to lead in immunology and address rare diseases.

The Gazette
Jun 2nd, 2025
Sanofi to buy US biopharma group Blueprint for up to $9.5 billion

PARIS (Reuters) -France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European healthcare company so far this year, according to LSEG data.

GlobeNewswire
Jun 2nd, 2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...